Molecular Health To Attend Key Events and Scientific Conferences In The Third Quarter 2018
(PresseBox) - Molecular Health (MH), a leading biomedical company that is transforming molecular data into clinically actionable information for efficient and safer cancer treatment options based on its proprietary Dataome® technology platform, announced that the company is going to attend several industry and scientific conferences in the third quarter 2018.
July
The 16th Annual Meeting of Japanese Society of Medical Oncology JSMO, July 19 - 21, 2018 - Kobe International Conference Center, Japan. Attendance: 3 posters and 1 oral presentation
MH BRCA ? Confident BRCA1/2 variant classification: using ACMG and public data for systematic molecular profiling
Intelligent treatment decision support combining variant interpretation and phenotype analytics can transform healthcare
Comprehensive treatment decision support of more than 1,000 patients by the medical device Molecular Health Guide®
Evidence-based software for NGS in pancreatic cancer: first results from the PePaCaKa study
August
The 9th Annual Cancer Genomics Consortium CGC Meeting, August 6 ? 8, 2018 - Nashville, TN, USA. Attendance: Molecular Health booth.
September
Molekularpathologie-Symposium, September 5-9, Gera, Germany. Attendance: lecture from Dr. Stephan Brock CTO of Molecular Health.
Heidelberger Myelomtage, September 21 ? 23, 2018 ? Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Attendance: Molecular Health booth.
ISPOR Asia Pacific 2018, September 8 ? 11, 2018 ? Kei Plaza Hotel, Tokyo, Japan. Attendance: Poster presentation.
MH EFFECT® - A novel technology for the molecular analyses of real world outcomes/adverse event data.
Molecular Health (MH) is a computational biomedicine company focused on the capture, curation, integration, and analysis of large data sets in the field of biomedicine and medical products and combining them with novel artificial intelligence and machine learning (AI/ML) technologies to enable precision medicine. Over more than a decade, the company has developed Dataome®, a unique, highquality curated, interoperable system that combines clinico-molecular drug data and analytical processes. Dataome, in combination with novel AI/ML technologies, creates a totally new approach for prognostic and predictive in silico science that can guide some of the most promising yet most challenging domains of precision medicine.
For more information, visit www.molecularhealth.com
Unternehmensinformation / Kurzprofil:
Molecular Health (MH) is a computational biomedicine company focused on the capture, curation, integration, and analysis of large data sets in the field of biomedicine and medical products and combining them with novel artificial intelligence and machine learning (AI/ML) technologies to enable precision medicine. Over more than a decade, the company has developed Dataome®, a unique, highquality curated, interoperable system that combines clinico-molecular drug data and analytical processes. Dataome, in combination with novel AI/ML technologies, creates a totally new approach for prognostic and predictive in silico science that can guide some of the most promisingyet most challenging domains of precision medicine.For more information, visit www.molecularhealth.com
Datum: 02.07.2018 - 11:40 Uhr
Sprache: Deutsch
News-ID 577676
Anzahl Zeichen: 2737
contact information:
Town:
Heidelberg, Germany / Boston, USA
Kategorie:
Manufacturing & Production
Diese Pressemitteilung wurde bisher 288 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Molecular Health To Attend Key Events and Scientific Conferences In The Third Quarter 2018"
steht unter der journalistisch-redaktionellen Verantwortung von
Molecular Health GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
